{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T00:32:14Z","timestamp":1648945934282},"reference-count":52,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.9625","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T12:25:17Z","timestamp":1610022317000},"source":"Crossref","is-referenced-by-count":0,"title":["Somatically acquired mutations in primary myelofibrosis: A case report and meta\u2011analysis"],"prefix":"10.3892","volume":"21","author":[{"given":"Yongming","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Hematology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxiao","family":"Hong","sequence":"additional","affiliation":[{"name":"Medical Genetics Center, School of Medicine at Ningbo University, Ningbo, Zhejiang 315211, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhibin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Duan","sequence":"additional","affiliation":[{"name":"Medical Genetics Center, School of Medicine at Ningbo University, Ningbo, Zhejiang 315211, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"key20220302133819_b1-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s12098-010-0340-6","article-title":"Idiopathic myelofibrosis in an infant","volume":"78","author":"Bavikar","year":"2011","journal-title":"Indian J Pediatr"},{"key":"key20220302133819_b2-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12185-013-1353-5","article-title":"Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms","volume":"97","author":"Bhagwat","year":"2013","journal-title":"Int J Hematol"},{"key":"key20220302133819_b3-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/s0145-2126(00)00136-3","article-title":"New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia","volume":"25","author":"Cox","year":"2001","journal-title":"Leuk Res"},{"key":"key20220302133819_b4-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/jcp.2010.080895","article-title":"Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases","volume":"64","author":"Tognon","year":"2011","journal-title":"J Clin Pathol"},{"key":"key20220302133819_b5-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0145-2126(00)00018-7","article-title":"Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: A report on 15 patients","volume":"24","author":"Bouabdallah","year":"2000","journal-title":"Leuk Res"},{"key":"key20220302133819_b6-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20220302133819_b7-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/156800911793743592","article-title":"Current treatment concepts of Philadelphia-negative MPN","volume":"11","author":"Wolf","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"key20220302133819_b8-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05301.x","article-title":"Modern management of myelofibrosis","volume":"128","author":"Cervantes","year":"2005","journal-title":"Br J Haematol"},{"key":"key20220302133819_b9-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","article-title":"Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups","volume":"102","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"key":"key20220302133819_b10-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/hon.863","article-title":"Familial chronic myeloproliferative disorders: The state of the art","volume":"26","author":"Rumi","year":"2008","journal-title":"Hematol Oncol"},{"key":"key20220302133819_b11-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20220302133819_b12-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: Mutations, inhibitors, and resistance","volume":"19","author":"Quintas-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"41","key":"key20220302133819_b13-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-4-41","article-title":"Recent advances in the bcr-abl negative chronic myeloproliferative diseases","volume":"4","author":"Bennett","year":"2006","journal-title":"J Transl Med"},{"key":"key20220302133819_b14-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"26834","DOI":"10.18632\/oncotarget.25515","article-title":"Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2","volume":"9","author":"Ishida","year":"2018","journal-title":"Oncotarget"},{"key":"key20220302133819_b15-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"842","DOI":"10.7534\/j.issn.1009-2137.2018.03.035","article-title":"Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms","volume":"26","author":"He","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20220302133819_b16-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"key20220302133819_b17-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.11406\/rinketsu.60.1166","article-title":"The differential diagnosis of classical myeloproliferative neoplasms (MPN): The updated WHO criteria","volume":"60","author":"Kvasnicka","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"key20220302133819_b18-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20220302133819_b19-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"65","DOI":"10.22088\/cjim.9.1.65","article-title":"BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran","volume":"9","author":"Ayatollahi","year":"2018","journal-title":"Caspian J Intern Med"},{"key":"key20220302133819_b20-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3329\/bmrcb.v39i2.19644","article-title":"Development and evaluation of an in-house ELISA to detect hepatitis B virus surface antigen in resource-limited settings","volume":"39","author":"Fatema","year":"2013","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"103","key":"key20220302133819_b21-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-103","article-title":"Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis","volume":"10","author":"Friedrich-Rust","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"key20220302133819_b22-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jcp.54.9.657","article-title":"Bone marrow aspiration","volume":"54","author":"Bain","year":"2001","journal-title":"J Clin Pathol"},{"key":"key20220302133819_b23-etm-0-0-09625","first-page":"232","article-title":"Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation","volume":"14","author":"Wang","year":"2006","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20220302133819_b24-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"834","DOI":"10.29271\/jcpsp.2018.11.834","article-title":"Sonographic evaluation of normal liver, spleen, and renal parameters in adult population: A multicenter study","volume":"28","author":"Khan","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"key":"key20220302133819_b25-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ajh.2830350405","article-title":"Dry tap bone marrow aspiration: Clinical significance","volume":"35","author":"Humphries","year":"1990","journal-title":"Am J Hematol"},{"key":"key20220302133819_b26-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/1042819022386608","article-title":"Myelodysplasia and bone marrow fibrosis treated with calcitriol and venesection","volume":"43","author":"Hirri","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"e7464","key":"key20220302133819_b27-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007464","article-title":"Progression of primary myelofibrosis to polycythemia vera: A case report","volume":"96","author":"Guo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key20220302133819_b28-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1634\/theoncologist.8-3-225","article-title":"The forgotten myeloproliferative disorder: Myeloid metaplasia","volume":"8","author":"Tefferi","year":"2003","journal-title":"Oncologist"},{"key":"key20220302133819_b29-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/08880010490276917","article-title":"Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome","volume":"21","author":"Narendran","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"key":"key20220302133819_b30-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.htct.2019.03.001","article-title":"Guideline on myeloproliferative neoplasms: Associac\u00e3o brasileira de hematologia, hemoterapia E terapia cellular: Project guidelines: Associa\u00e7\u00e3o m\u00e9dica brasileira-2019","volume":"41 (Suppl)","author":"Tavares","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"key20220302133819_b31-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000450956","article-title":"Molecular pathogenesis and clinical significance of driver mutations in primary myelofibrosis: A review","volume":"25","author":"Alshemmari","year":"2016","journal-title":"Med Princ Pract"},{"key":"key20220302133819_b32-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/j.seminhematol.2005.08.002","article-title":"Lessons from familial myeloproliferative disorders","volume":"42","author":"Skoda","year":"2005","journal-title":"Semin Hematol"},{"key":"key20220302133819_b33-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bcmd.2012.06.004","article-title":"Long term follow up of 93 families with myeloproliferative neoplasms: Life expectancy and implications of JAK2V617F in the occurrence of complications","volume":"49","author":"Malak","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"key20220302133819_b34-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ajh.2830460312","article-title":"Familial myeloproliferative syndrome","volume":"46","author":"Perez-Encinas","year":"1994","journal-title":"Am J Hematol"},{"key":"key20220302133819_b35-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00043426-200403000-00005","article-title":"Fatal familial infantile myelofibrosis","volume":"26","author":"Sheikha","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20220302133819_b36-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3324\/haematol.12706","article-title":"Aberrant expression of microRNA in polycythemia vera","volume":"93","author":"Bruchova","year":"2008","journal-title":"Haematologica"},{"key":"key20220302133819_b37-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"key20220302133819_b38-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2009-01-197525","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms","volume":"114","author":"Saint-Martin","year":"2009","journal-title":"Blood"},{"key":"key20220302133819_b39-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: Analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"key":"key20220302133819_b40-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"key20220302133819_b41-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"key20220302133819_b42-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"key20220302133819_b43-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"key":"key20220302133819_b44-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"key20220302133819_b45-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/leu.2009.167","article-title":"Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis","volume":"24","author":"Tanaka","year":"2010","journal-title":"Leukemia"},{"key":"key20220302133819_b46-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2004.02.002","article-title":"Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders","volume":"19","author":"Kralovics","year":"2005","journal-title":"Blood Rev"},{"issue":"2","key":"key20220302133819_b47-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-2","article-title":"Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis","volume":"5","author":"Tognon","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20220302133819_b48-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.beha.2006.11.005","article-title":"The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age","volume":"20","author":"Kaushansky","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20220302133819_b49-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2430","article-title":"Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology","volume":"36","author":"Latagliata","year":"2018","journal-title":"Hematol Oncol"},{"issue":"78","key":"key20220302133819_b50-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20220302133819_b51-etm-0-0-09625","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"49","key":"key20220302133819_b52-etm-0-0-09625","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1062-x","article-title":"Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms","volume":"38","author":"Hu","year":"2019","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:42:09Z","timestamp":1646221329000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.9625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,1,7]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.9625","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"article-number":"193"}}